Please login to the form below

Not currently logged in
Email:
Password:

VentiRx appoints James Kyle Bryan as chief medical officer

He has more than 20 years of experience in oncology

US-based biopharma VentiRx Pharmaceuticals has appointed Dr James Kyle Bryan as chief medical officer.

Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.

During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology.

This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian cancer and head and neck cancer.

“His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward,” said Dr Robert Hershberg, CEO of VentiRx. “We are delighted to have him join the VentiRx team.”

30th April 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....